EML4-ALK, PIK3CA, and MEK1 mutations occurred in NSCLC with various distinct clinicopathological characteristics.     ///    "EML4-ALK, PIK3CA, and MEK1 mutations were mutually exclusive. "    ///    "EML4-ALK, PIK3CA, and MEK1 mutations were mutually exclusive."    ///    "Furthermore, tumors with EML4-ALK fusions had significantly higher levels of ERCC1, a molecule with a key role in platinum drug efficacy, than tumors without EML4-ALK fusions. "    ///    EML4-ALK fusion was found to be of coexistence with EGFR and KRAS mutations in two cases.     ///    EML4-ALK fusions could serve as a significant prognostic indicator for locally advanced NSCLC..     ///    "Moreover, multivariate analysis indicated that in stage IIIA NSCLC EML4-ALK fusion was the only significant indicator for poor DFS (P < 0.001). "    ///    "Of 488 patients with NSCLC, 28 had EML4-ALK fusions. "    ///    "Furthermore, tumors with EML4-ALK fusions had significantly higher levels of ERCC1, a molecule with a key role in platinum drug efficacy, than tumors without EML4-ALK fusions."